**OTC DISCLOSURE AND NEWS SERVICE**

# COMPANY INFORMATION AND DISCLOSURE STATEMENT

(Feb. 15, 2016)

# HANNOVER HOUSE, INC.

**(Pinksheets: HHSE)**

| **WYOMING** | **91-1906973** |
|---|---|
| **(State of Incorporation)** | **(IRS Employer Identification No.)** |

**1428 CHESTER STREET**
**SPRINGDALE, AR 72764**
**(Address of Principal Executive Offices)**

**479-751-4500**
**(Issuer's Telephone Number)**

**Cusip Number 410681 101**

## NOTIFICATION OF ISSUES, ITEMS AND UPDATES FOLLOWING BOARD OF DIRECTOR'S MEETING OF FEB. 10, 2016

## POSTED: Feb. 15, 2016

HANNOVER
HOUSE

# TABLE OF CONTENTS

**Posted February 15, 2016**


| | | |
|---|---|---|
| **ITEM 1** | **Issues, Items and Updates on Various Corporate Matters as Discussed or Otherwise Acted Upon At Board of Director's Meeting, Feb. 10, 2016** | **Page 3** |
| **ITEM 2** | **Certifications** | **Page 4** |


## FORWARD-LOOKING STATEMENTS

This disclosure statement contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terms such as "may", "intend", "will", "could", "would", "expects", "believe", "estimate", or the negative of these terms, and similar expressions intended to identify forward-looking statements.

These forward-looking statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Also, these forward-looking statements present our estimates and assumptions only as of the date of this disclosure statement. Except for our ongoing obligation to disclose material information as required by federal securities laws, we do not intend to update you concerning any future revisions to any forward-looking statements to reflect events or circumstances occurring after the date of this disclosure statement.

Actual results in the future could differ materially and adversely from those described in the forward-looking statements as a result of various important factors, including the substantial investment of capital required to produce and market films and television series, increased costs for producing and marketing feature films, budget overruns, limitations imposed by our credit facilities, unpredictability of the commercial success of our motion pictures and television programming, the cost of defending our intellectual property, difficulties in integrating acquired businesses, and technological changes and other trends affecting the entertainment industry.

**ITEM 1)** – A meeting of the Board of Directors of Hannover House, Inc. was held on Wednesday, February 10, at 10:00 am, at the Company's principal office headquarters in Springdale, Arkansas. Due to a delay in activation of the Directors and Officer's Liability Insurance for all Company board members, nominated board members Tom Sims and Eric Doctorow were excused from attendance. The following items are summarized and represent those issues requiring disclosure of any action or approvals of the Board of Directors.

**1). ANNUAL SHAREHOLDER'S MEETING** – The Board of Director's Voted to Hold the HHSE ANNUAL SHAREHOLDER'S MEETING on Friday, March 18 at 10:30 am at the Hyatt Regency, Century Plaza Hotel, 2025 Avenue of the Stars, Los Angeles, CA 90067. Shareholders of Record as of Dec. 15, 2015 may register for attendance by sending an email to: Katherine@HannoverHouse.com. A public agenda of items to be covered at the annual shareholder's meeting will be posted at least seven (7) days prior to the meeting. The Board elected to hold the meeting this year in Los Angeles, in order to accommodate attendance and measure the location's response. Prior meetings held in Fayetteville, Arkansas and New York City generated only minimal shareholder attendance. Due to the large number of HHSE new venture partners located in the Los Angeles market, the Board felt that a meeting site in Los Angeles might attract more attendance than in recent years.

**2). BOARD APPROVAL OF MAJOR NEW PRODUCTION & DISTRIBUITON VENTURES –** In respect of licensing activities now underway at Berlin (EFM) and with other, targeted international sales partners and distributors, the Board felt that communications to shareholders of certain projects representing significant value to the Company be disclosed. The following is a brief summary of high-profile projects that HHSE and Medallion Releasing are contracted to represent, and which are expected to enhance the visibility and revenues of the Company. In order to preserve certain proprietary restrictions on announcing specific cast members and production details, HHSE will only disclose those items of title, genre and overall funding / releasing mechanisms. The listing of these projects below in Alphabetical order is not intended to imply a specific ranking of priority or anticipated revenue strength.

**a). DELIRIUM** – Sci-Fi / Horror Feature *(one major star)* – Private Investor financing will cover all production costs, plus fund a 'seed' theatrical P&A budget for HHSE / Medallion. Incoming foreign sales revenues will be used to supplement the North American P&A fund. Film is slated to commence filming in April / promo reel at CANNES.

**b). LEGEND OF BELLE STARR** – Action-Adventure / Western *(two major stars)* – Private Investor financing will cover all production costs and theatrical P&A. Commencement of principal photography is conditioned upon coordination of schedules of principals.

**c). MAXIMUM IMPLUSE** – Action-Adventure *(three major stars)* – Private Investor financing will cover all production costs and theatrical P&A. Principal photography is expected to commence in October, with a promo reel for HHSE / Medallion to present at the AFM / IFTA market.

**d). MELTDOWN** – Action-Adventure (one major star) – Private Investor financing will cover all production costs and theatrical P&A. Principal photography is expected to commence in September, with a promo reel for HHSE / Medallion to present at the AFM / IFTA market.

**e). MOTHER GOOSE: JOURNEY TO UTOPIA** – Adventure / Fantasy / *Family (three major stars)* – Financing is still being assembled, but is expected to include a basis of approximately 40% "international presales" which will be supplemented with a facility co-production deferral, state rebates and bank "gap" financing. Commencement of principal photography will need to coordinate the closure of funding elements, with the mutual availabilities of the principal talent.

**f). OVER THE EDGE -** Action-Adventure *(one major star)* – Private Investor financing will cover all production costs, plus fund a 'seed' theatrical P&A budget for HHSE / Medallion. Incoming foreign sales revenues will be used to supplement the North American P&A fund. Film is slated to commence filming in late April / early May with a promo reel for CANNES.

**g). PATHWAY TO FREEDOM** – Historic / Drama *(one major star)* – Private Investor financing will cover all production costs, plus fund a 'seed' theatrical P&A budget for HHSE / Medallion. Incoming foreign sales revenues will be used to supplement the North American P&A fund. Film is slated to commence filming in August / promo reel at AFM / IFTA

**h). UTOPIA** – Long-form Music Feature *(five major stars)* – Private Investor financing will cover all production costs, and all theatrical P&A costs, including soundtrack (CD and Digital platforms). Principal photography has commenced, HHSE to present "promo reel" and worldwide release announcement at the Cannes Film Festival / Marche du Filme (May 11 – 22).

Each of the above eight (8) major productions are expected to be released by HHSE / Medallion to theatres in the USA and Canada at a level that would meet the standards of a "national" or "wide" release breadth. Each of the above feature productions is being financed by private investors or through a combination of private investor funding, co-production ventures, "banking" or presales or tax incentives / credits – and none of the above films requires an out of pocket investment by Hannover House, Inc., nor calls for the issuance of HHSE stock shares.

The Company is also handling the April 22 theatrical release of "**UNION BOUND**" to approximately 165 theatres in most of the USA's top 50 largest markets, and an "**UNTITLED ROMANTIC COMEDY**" *(completed feature, still awaiting title clearance*), which will be released to all major markets on or about June 17, 2016. In addition to the eight major productions and two mid-level theatrical releases listed above, the Company is also involved in both the production and worldwide distribution of six "lower-budgeted" productions, which may or may not ultimately merit more than a small "platform" theatrical releases. The Eight (8) major new titles, plus the Two (2) mid-level theatrical releases and the Six (6) lower-budgeted productions are collectively expected to drive the majority of revenues for HHSE and Medallion during 2016 and 2017. The Company expects to release a total of thirty-two (32) titles to the Home Video / VOD Market during 2016, which include some of the above items, but which list is primarily comprised of direct-to-video or "limited-release theatrical" titles to the home video market / VOD markets under the HHSE and Medallion labels.

* * * * *

There being no other business to conduct, discuss or approve by the Board, the meeting was adjourned at 11:30 am.

**ITEM 2 - Certifications**

I, ERIC F. PARKINSON, hereby certify that;

(1) I have reviewed the filing of February 15, 2016 covering issues and items from the Board of Director's Meeting of February 10, 2016, as voluntarily published by the Company;

(2) Based on my knowledge, this Disclosure Statement not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Disclosure Statement; and

(3) Based on my knowledge, the financial information included or incorporated by reference in this Disclosure Statement fairly present in all material respects the financial condition, results of operations, and cash flows of the Issuer as of, and for, the periods presented in this Disclosure Statement.

Dated: 15 February 2016

/s/ ERIC PARKINSON
By: Eric F. Parkinson
Title: Chairman and Chief Executive Officer